Any current/future new fundraising through debt or equity?

There is no specific mention of any immediate new fundraising through debt or equity in the transcript. Funding for new projects, such as the Yeswanthpur hospital in Bangalore, will be through a mix of internal and external funds. The company has strong cash flows from operations, converting more than 80-85%, and expects internal accruals to cover most funding needs. At the combined level of Aster and QCIL, net debt is near zero as of FY24, indicating a strong balance sheet. No material increase in debt is expected; any debt on QCIL is significantly lower than their EBITDA. Capex for expansion

Any current/future capex/capital investment/strategic investment?

Aster is adding approximately 2,600 beds over the next 3-4 years, requiring about INR 2,500 crores in project CAPEX, with INR 400-500 crores already spent as of June 30; the remaining INR 2,000 crores to be spent over the next years. For the current FY26, cumulative CAPEX including projects is estimated between INR 800 to 900 crores. New projects like the Yeswanthpur hospital in Bangalore are greenfield developments funded through a mix of internal accruals and external funds, with CAPEX spread over roughly 20 months. Brownfield expansions are EBITDA accretive with minimal margin dilutio

Future growth expectations in sales/revenue/volumes?

Aster DM Healthcare expects 7-8% growth in both volumes and ARPOB (Average Revenue Per Occupied Bed) for FY26. Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in Q4 FY25. The company anticipates returning to double-digit growth in volumes and revenue within a couple of quarters. Over a longer 3-4 year horizon, a 7-8% sustainable ARPOB growth is targeted, supported by specialty mix changes and oncology growth. New hospital expansions and bed additions (2,600 beds by Aster and 1,200 beds

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue growth is expected to return to double-digit figures within a couple of quarters, following a subdued performance in recent quarters due to leadership changes and specific decisions (Page 21). Mid-term growth (3-4 years horizon) is projected at mid-teen levels, split roughly equally between volume growth (7-8%) and ARPOB (Average Revenue Per Occupied Bed) growth (7-8%) (Page 12). ARPOB growth drivers include price increases, case mix improvements (notably oncology), and efficient ALOS (Average Length of Stay) management, supporting sustainable margin expansion (Pages 15-17). Brownfi

Current/ Expected Orderbook/ Pending Orders?

For Aster DM Healthcare, the project capex for adding approximately 2,600 beds is about INR 2,500 crores. Out of this, INR 400 to 500 crores have already been incurred as of 30th June. The remaining INR 2,000 crores is expected to be spent over the next 3-4 years. For QCIL, cumulative CAPEX outlay including upcoming projects is expected to be about INR 800 to 900 crores this year. Yearly operational CAPEX is roughly 5% of the topline, consistent with prior years. Brownfield expansions, such as adding 100 beds in Kerala clusters, have a positive impact on EBITDA and margins with immediate accre

IN US

Sale is live|00:00:00left today

Aster DM Healthcare LtdQ2 FY25Healthcare Services

Aster DM Healthcare Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹769P/E: 89.0Market Cap: ₹36.3K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Aster DM Healthcare expects 7-8% growth in both volumes and ARPOB (Average Revenue Per Occupied Bed) for FY26.
→Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in Q4 FY25.
→The company anticipates returning to double-digit growth in volumes and revenue within a couple of quarters.
→Over a longer 3-4 year horizon, a 7-8% sustainable ARPOB growth is targeted, supported by specialty mix changes and oncology growth.
→New hospital expansions and bed additions (2,600 beds by Aster and 1,200 beds by QCIL in pipeline) are expected to drive future revenue growth.
→OPD (Outpatient Department) business is growing fast (12% volume growth) and expected to contribute favorably to ARPOB and overall revenue growth.
→The company aims to continue ramping up new units rapidly, with some showing top-line growth of 25% quarter-over-quarter.

Margin guidance

Category 3

→Revenue growth is expected to return to double-digit figures within a couple of quarters, following a subdued performance in recent quarters due to leadership changes and specific decisions (Page 21).
→Mid-term growth (3-4 years horizon) is projected at mid-teen levels, split roughly equally between volume growth (7-8%) and ARPOB (Average Revenue Per Occupied Bed) growth (7-8%) (Page 12).
→ARPOB growth drivers include price increases, case mix improvements (notably oncology), and efficient ALOS (Average Length of Stay) management, supporting sustainable margin expansion (Pages 15-17).
→Brownfield expansions are EBITDA and margin accretive with minimal payback period impact; greenfield payback period estimated around 9-10 years, with capex around INR 1-1.1 crore per bed (Pages 12-13).
→Andhra & Telangana cluster EBITDA margins dip expected to normalize to 12-13% in coming quarters after initial clinical talent onboarding costs (Page 23).
→Optimizations and synergies post-merger (e.g., insourcing, revenue cycle management) are expected to drive further profitability improvements (Page 17).

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→There is no specific mention of any immediate new fundraising through debt or equity in the transcript.
→Funding for new projects, such as the Yeswanthpur hospital in Bangalore, will be through a mix of internal and external funds.
→The company has strong cash flows from operations, converting more than 80-85%, and expects internal accruals to cover most funding needs.
→At the combined level of Aster and QCIL, net debt is near zero as of FY24, indicating a strong balance sheet.
→No material increase in debt is expected; any debt on QCIL is significantly lower than their EBITDA.
→Capex for expansions (like the 2,600 new beds) will be around INR 2,500 crores over 3-4 years, with INR 400-500 crores already spent.
→Therefore, future funding will largely rely on internal resources with selective external funding as needed, not highlighting any major new equity or debt raise.

Order book

→For Aster DM Healthcare, the project capex for adding approximately 2,600 beds is about INR 2,500 crores.
→Out of this, INR 400 to 500 crores have already been incurred as of 30th June.
→The remaining INR 2,000 crores is expected to be spent over the next 3-4 years.
→For QCIL, cumulative CAPEX outlay including upcoming projects is expected to be about INR 800 to 900 crores this year.
→Yearly operational CAPEX is roughly 5% of the topline, consistent with prior years.
→Brownfield expansions, such as adding 100 beds in Kerala clusters, have a positive impact on EBITDA and margins with immediate accretion.
→Greenfield projects like the new Bangalore hospital have a CAPEX timeline of around 20 months to 1.5-2 years.

Capex plans

Yes

→Aster is adding approximately 2,600 beds over the next 3-4 years, requiring about INR 2,500 crores in project CAPEX, with INR 400-500 crores already spent as of June 30; the remaining INR 2,000 crores to be spent over the next years.
→For the current FY26, cumulative CAPEX including projects is estimated between INR 800 to 900 crores.
→New projects like the Yeswanthpur hospital in Bangalore are greenfield developments funded through a mix of internal accruals and external funds, with CAPEX spread over roughly 20 months.
→Brownfield expansions are EBITDA accretive with minimal margin dilution and faster payback compared to greenfield expansions, which have a payback of about 9-10 years.
→QCIL also has a pipeline of about 1,200 beds that are being added or expanded.
→Overall, the group targets around 14,000 beds over 2-3 years combining Aster and QCIL expansions.

How does Aster DM Healthcare Ltd rank vs peers in Healthcare Services?

Pro feature

1Aster DM Healthcare Ltd

Rev 3Mar 3

See full Healthcare Services sector rankings

Want more stocks like Aster DM Healthcare Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio